Overview

Immuno-oncology, and the advent of checkpoint inhibitors, profoundly revolutionized the treatment of cancers by making cancer-free outcome a reality. Unfortunately, after more than a decade of drug development, only 20% of patients are responding to these blockbuster immunotherapies, which leaves 80% of patients without any therapeutic solutions. 

At TATUM bioscience we are dedicated to solving this major unmet medical need.

For that, we have developed a completely new therapeutic approach called nanofilament vaccine immunotherapy.  TATUM’s nanofilaments are a first-in-class modality that uncloaks cancer cells and orchestrate the immune system to trigger powerful and long-lasting antitumor vaccine responses, providing unparalleled response rates and therapeutic efficacy.

The company leverages a proprietary synthetic biology platform allowing light-speed drug development, and TAT003 (our lead candidate) achieves stellar efficacy in anti-PD(L)1 resistant model (while having a derisked safety profile. 

After raising a pre-seed and a seed, we are currently gearing up to Series A funding, to bring TAT003 to the clinic. We are supported by a team of world renown oncologists from leading cancer centers (e.g. MD Anderson), as well as former experienced pharma/biotech board members, who all truly believe that TATUM will make an impact on the live of cancer patients.